NeurAxis Gains FDA Clearance for Pediatric Treatment, Doubling Addressable Market NeurAxis Inc. (NRXS) has secured a major regulatory milestone, receiving FDA 510(k) clearance for its IB-Stim™ device to treat Functional Dyspepsia (FD) and a

Big win for #NeurAxisInc! ( #NRXS)
FDA clears IB-Stim for pediatric IBS treatment, doubling their market to 16M patients. Transforming lives with innovative neuromodulation!
#Healthcare #MedTech #NRXS #neuromodulation
prismmarketview.com/neuraxis-gai...